BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl (NASDAQ: CELG) today announced updated results from a retrospective analysis of a randomised, international phase III study of REVLIMID® (lenalidomide) for the treatment of patients with low/int-1 risk myelodysplastic syndromes (MDS) with a del(5q) chromosome abnormality. These results were presented during the 52nd Annual Meeting of the American Society of Hematology in Orlando, FL.
